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Abstract
Eczema is a chronic relapsing atopic dermatitis (AD) associated with pruritus, sleep disturbance and poor quality of
life of the patient. Treatment of eczema includes use of emollient, topical and systemic antimicrobial agents,
corticosteroid or immunomodulating agents. Many patients also seek alternative treatments such as dietary
avoidance, supplementation or both. This article reviews the basic pathophysiology of eczema and clinical trials
involving Chinese medicine in the treatment of eczema. Research reports on Chinese herbal medicine for eczema
were retrieved from PubMed and the Cochrane Database for Systematic Reviews for this review. Only a few RCTs
demonstrated the efficacy (or lack of efficacy) of Chinese medicinal herbs in treating atopic eczema. Further larger
scale trials are warranted.
Introduction
Atopic dermatitis (AD) is a chronically relapsing inflam-
matory skin disease commonly associated with allergy
[1,2]. About 15% of children suffer from this disease
[2-4]. Typical onset of the disease is occurs in the chil-
dren under five years of age [2,5]. The condition
improves in most patients before adulthood. Manage-
ment of this condition includes use of emollient, topical
and systemic antimicrobial agents, corticosteroid or
immunomodulating agents [2]. Corticosteroids (CS) are
the common treatment for AD in either topical or sys-
temic form. CS has a wide range of immunomodulatory
effects, such as the suppression of cytokine production,
adhesion molecule expression and leukocyte chemotaxis
[6]. CS is also associated with deranged metabolism,
growth suppression and increased susceptibility to infec-
tions. In particular, the use of potent topical CS in AD
may cause significant suppression of the hypothalamic-
pituitary-adrenal axis [7]. More specific immunomodula-
tory agents (eg topical tacrolimus) are available [2,8]. As
there is still no cure for AD, various dietary therapies
including Chinese medicine are adopted by the patients,
especially in Asia [9]. However, the beneficial effects of
Chinese medicine on children with AD have not been
consistently demonstrated [10]. A limited number of
Chinese medicine trials in children and adults with AD
did not show convincing results [11-14].
Pathogenesis
Pathogenesis of AD involves complex interactions between
susceptible genes (filaggrin genes), immunological factors
(immunoglobulin E, eosinophils, T helper cells, chemo-
kines), skin barrier defects, infections, neuroendocrine fac-
tors (brain derived neurotrophic factor) and
environmental factors (weather change, food and aeroal-
lergens) [1,2,15,16]. Major components in immune dysre-
gulation include Langerhans’ cells, inflammatory dendritic
epidermal cells, monocytes, macrophages, lymphocytes,
mast cells and keratinocytes.A l lo ft h e s ec o m p o n e n t s
interact through an intricate cascade of cytokines leading
to a predominance of Th2 cells [16]. Th2 cytokines, inter-
leukins IL-4, IL-5, IL-10 and IL-13, increase in the skin
while there is a corresponding decrease in Th1 cytokines,
mainly interferon-g and IL-2 [2].
Changes in the epidermis are attributed to the xerotic
skin in AD patient. Essential fatty acids (EFAs) are
important components of the epidermis. Loss of EFAs
results in increased transepidermal water loss and subse-
quent xerosis (dryness). Defects in the epidermal barrier
also lead to increased susceptibility to allergens such as
house dust mites, grass or pollen. When such allergens
are in contact with susceptible skin, they stimulate Th2
l y m p h o c y t e st op r o d u c ec y t o k i n e ss u c ha sI L - 4 ,I L - 5
and IL-13 which in turn promote an increase in IgE
* Correspondence: ehon@hotmail.com
1Departments of Paediatrics, The Chinese University of Hong Kong, Prince of
Wales Hospital, Shatin, Hong Kong SAR, China
Full list of author information is available at the end of the article
Hon et al. Chinese Medicine 2011, 6:17
http://www.cmjournal.org/content/6/1/17
© 2011 Hon et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.synthesis [2,17,18]. AD patients often have high levels of
IgE antibodies in response to house dust mites and
other allergens [19,20].
AD patients also often have defective cell-mediated
immunity, which is attributed to increased susceptibility
to many bacterial, viral and fungal infections of the skin
[2]. Certain factors, including Staphylococcus aureus
colonization, stress, anxiety, systemic illness and xerosis,
exacerbate or trigger AD [2].
According to Chinese medicine theory [21], Qi can be
disrupted by ‘wind’, ‘coldness’, ‘summer-heat’, ‘damp-
ness’, ‘dryness’ or ‘fire evils’. Main pathogenic factors of
eczema are thought to be ‘wind’, ‘dampness’ and ‘heat’
[21]. Herbs such as Cortex Moutan Radix (Danpi),
Radix Paeoniae Alba (Bai Shao), Potentilla Chinensis
Ser (Weilingcai) and Radix Glycyrrhizae (Gan Cao)a r e
common treatments for allergy [22]. Flos Lonicerae (Jin-
gyinhua)a n dHerba Menthae (Bohe)c l e a r‘damp-heat’
from the exterior, Cortex Moutan (Danpi)c l e a r s‘heat’
from blood while Rhizoma Atractylodis (Cangzhu)a n d
Cortex Phellodendri (Huangbai)c l e a rt h e‘damp-heat’
from the interior. Pharmacological studies indicate that
these herbs have anti-allergic, anti-inflammatory and
sedative action for itchiness [21,23,24].
This article aims to review randomized trials, case ser-
ies and bench studies in Chinese medicine for eczema.
For this review, as of December 2010, we retrieved 47
articles from PubMed using the keywords “’Chinese her-
bal medicine’ and (’atopic dermatitis’ or ‘eczema’)”.W e
also searched the Cochrane Database for Systematic
Reviews. Using PubMed Clinical Queries, we retrieved
9, 2 and 9 references under Clinical Study Categories,
Systematic Reviews and Medical Genetics respectively.
All RCTs and relevant case series and bench studies
were included. Review articles that did not provide any
information on eczema and Chinese medicine were
excluded.
Randomized trials
There have been only a few randomized trials in this
region on Chinese medicine treatment for AD (Table 1).
Cochrane systematic review in 2005 on the topic of Chi-
nese herbal medicine for AD included only four clinical
trials [13].
Zemphyte trials
In the early 1990s, a decoction (Zemaphyte, Phytopharm
Plc, UK) was efficacious for the treatment of AD in
both children [25,26] and adults [27] in the UK. Shee-
han et al. carried out a randomized placebo-controlled
double-blind trial of a specific prescription formulated
for widespread non-exudative atopic eczema [25]. Forty-
seven children were given active treatment and placebo
in random order, each for eight weeks, with an interven-
ing 4-week wash-out period. Thirty-seven children
received all the treatment and completed the study.
Active treatment was more effective than the placebo.
There was no evidence of hematological, renal or hepa-
tic toxicity. The authors concluded that the Chinese
medicinal herbs under their trial have a therapeutic
potential in treating eczema and other skin diseases.
The opportunity to continue treatment was offered to
the parents of 37 children who had completed a double-
blind placebo-controlled trial of the same formulation of
Chinese medicinal herbs for atopic eczema [26]. The
parents selected continued treatment in all cases, and
the progress of the children was monitored for 12
months. The aim was to reinforce the clinical
Table 1 Randomized trials on herbal medicine for eczema
Population Design Outcome Adverse
effects
Validity Remarks
Pediatric Randomized, double-
blind, placebo-
controlled, crossover
Clinical only Nil Not intention-to-treat due to dropouts,
no quality of life measurement
Efficacy not
concurred with
[11]
[25]
Adults Randomized, double-
blind, placebo-
controlled, crossover
Clinical only Nil Not intention-to-treat due to dropouts,
no quality of life measurement
Efficacy not
concurred with
[11]
[13,49]
Pediatric +
Adults
Randomized, double-
blind, placebo-
controlled, crossover
Clinical only Minor Intention-to-treat, no dropouts, no
quality of life measurement
No effects [11]
Pediatric Randomized, double-
blind, placebo-
controlled
Clinical + quality of life +
oral antihistamine and
topical steroid-sparing
Minor Intention-to-treat, no dropouts, quality
of life + oral antihistamine and topical
steroid usage sparing
Improved quality
of life and
steroid-sparing
[30]
Adults Randomized to 4
groups, saline as
control
Poorly defined total effective
rate and cured rate
Nil Apparently no dropouts, but very small
subgroups sizes, no quality of life
measurement
Effective, difficult
to assess efficacy
[31]
Adults Randomized, double-
blind, placebo-
controlled
Clinical + topical steroid and
tacrolimus-sparing
Minor Not intention-to-treat due to dropouts,
no quality of life measurement
Topical steroid
and tacrolimus-
sparing only
[32]
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gressively. At the end of the 12-month follow-up period,
18 were reported to have at least 90% reduction in
eczema activity scores, and five showed moderate
improvement. Fourteen children withdrew from the
study. Seven of the children discontinued treatment
without relapse; the other 16 required treatment to
maintain control of their eczema, but only four of these
still required daily treatment. Asymptomatic elevation of
serum aspartate aminotransferase (AST) to 7-14 times
normal values was noted on one occasion in two chil-
dren whose eczema after treatment was so well that the
therapy was stopped. Liver function became normal
after eight weeks. The authors suggested that these Chi-
nese medicinal herbs provided a therapeutic option for
children with the extensive atopic eczema which did not
respond to other treatments.
The adult patients with severe atopic eczema who had
completed a similar double-blind placebo-controlled
crossover trial were offered continued treatment for one
year [27]. Out of the 31 patients who completed the pla-
cebo-controlled study and after a washout period and
further treatment, 17 continued treatment (group 1), 11
chose not to continue treatment (group 2), one was lost
to follow-up and two patients continued treatment but
finally decided to stop treatment. At the end of the 12-
month period, 12 patients in group 1 had reduction
greater than 90% and the remaining five had reduction
greater than 60% in clinical scores from baseline values.
Clinical scores of patients in group 2 gradually deterio-
rated during the year. Difference between groups 1 and
2 in clinical scores was highly significant (P = 0.005 and
P = 0.002 for erythema and surface damage respec-
tively). At the end of the 12-month period, no patient in
group 1 discontinued treatment although eight patients
were on an alternate-day regimen by six months and
remained on this regimen until the end of the 12-month
period, and seven were able to control their eczema
with treatment throughout the period. The remaining
two patients continued on daily treatments. Toxicology
screening revealed no abnormalities in either blood
counts or biochemical parameters in all patients under
continued treatment. Improvement in disease was not
associated with any significant change in the levels of
serum IgE or peripheral blood lymphocyte subsets.
Despite the efficacy reported in the UK trials, a subse-
quent randomized placebo-controlled, cross-over trial
(RCT) of the same decoction in Hong Kong failed to
demonstrate beneficial effects on Chinese patients with
recalcitrant AD in Hong Kong [11]. Forty recruited
patients were given Zemaphyte and placebo in random
order, each for eight consecutive weeks with a 4-week
wash-out period in between. Scores based on the sever-
ity and extent of four clinical parameters (erythema,
surface damage, lichenification and scaling) were
recorded at baseline and at 4-weekly intervals through-
out the 20-week trial period. Thirty-seven patients com-
pleted the trial. There was general clinical improvement
throughout the trial period in both patient groups, irre-
spective of whether they received Zemaphyte or placebo
first. Zemaphyte, however, offered no statistically signifi-
cant treatment effect over placebo for all four clinical
parameters, except for lichenification at week 4. There
were no significant carry-over effects. The results of
blood tests for hematologic, renal and liver functions
were all normal throughout the trial. The investigators
concluded that Zemaphyte did not benefit the Chinese
patients with recalcitrant atopic dermatitis in their
study.
PentaHerbs trials
In a pilot study, Hon et al. evaluated the clinical and
biochemical effects of a Chinese medicine capsule (Pen-
taHerbs capsule) in children with AD [28]. After a run-
in period of four weeks, children old enough to manage
oral medication were admitted and their disease severity
was evaluated by the SCORing Atopic Dermatitis
(SCORAD) index. Blood samples were taken for com-
plete blood count, total and allergen-specific immuno-
globulin E (IgE), biochemical studies and inflammatory
markers of AD severity [serum cutaneous T cell-attract-
ing chemokine (CTACK), macrophage-derived chemo-
kine (MDC), thymus and activation-regulated
chemokine (TARC) and eosinophil cationic protein
(ECP)] prior to, and after three months of Chinese med-
icine use. Three PentaHerbs capsules twice a day were
prescribed for four months. Patients were followed up
monthly to ensure compliance, and SCORAD scores
were obtained at each visit. Five boys and four girls par-
ticipated in the study. All patients had detectable food
or inhalant-specific IgE in serum. There was significant
improvement in the overall and component SCORAD
scores. There were no significant differences between
the pre- and post-treatment values of the serum
CTACK, MDC, TARC and ECP levels but CTACK
showed a decreasing trend (P = 0.069). No clinical or
biochemical evidence of any adverse drug reaction was
found during the study period. The PentaHerbs capsules
were well tolerated by the children and apparent (reduc-
tion of disease severity) were noted clinically. The
authors concluded that a larger, randomized placebo-
controlled study is required to confirm the efficacy of
this formulation for AD.
The PentaHerbs capsules were manufactured, pack-
aged and labeled by the Chinese Medicine Industry
Development Centre, the Hong Kong Institute of Voca-
tion Education (Hong Kong, China). The composition of
each herb in the formulation was standardized. The
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1g r a mo fHerba menthae (Bohe), 2 grams of Cortex
moutan (Danpi), 2 grams of Rhizoma atractylodis
(Cangzhu)a n d2g r a m so fCortex phellodendri (Huang-
bai). The dosage calculation was based on the standard
Chinese medicine prescription for children (one bowl of
herbal tea) [28] and is equivalent to a daily dose of 20
ml of syrup. This dosage is adequate for children of this
age. The syrup was formulated and assessed for its qual-
ity and safety according to established procedures [28]
under the supervision of the Clinical Trials Section of
the Institute of Chinese Medicine (ICM) (Hong Kong,
China). In particular, the syrup had been tested for
heavy metals, microbial products and residual pesticides;
the results met the safety standards of Chinese medicine
in Hong Kong. A laboratory study found no corticoster-
oids in the five constituent herbs [29].
In a subsequent double-blinded randomized placebo-
controlled trial, the researchers assessed the efficacy and
tolerability of the decoction in children with AD [30].
Following a 2-week run-in period, children with long-
standing moderate-to-severe AD were randomized to
receive a 12-week treatment with a twice-daily dose of
three capsules of either PentaHerbs or placebo. The
SCORing of Atopic Dermatitis (SCORAD) score, Chil-
dren’s Dermatology Life Quality Index (CDLQI), allergic
rhinitis score, and requirement for topical corticosteroid
and oral antihistamine were assessed before and at
weeks 4, 8, 12 and 16 of treatment. Adverse events, tol-
erability, hematological and biochemical parameters
were monitored during the study. Eighty-five children
with AD were recruited. Over 12 weeks, the mean
SCORAD score fell from 58.3 to 49.7 in the PentaHerbs
group (n = 42; P = 0.003) and from 56.9 to 46.9 in the
placebo group (n = 43; P = 0.001). However, there was
no significant difference in the scores at the correspond-
ing time points between the two groups. The CDLQI of
PentaHerbs-treated group was more significantly
improved than that of the placebo group at the end of
the 3-month treatment and 4 weeks after stopping ther-
apy (P = 0.008 and 0.059 respectively). The total amount
of topical corticosteroid used was also significantly
reduced by one-third in the PentaHerbs group (P =
0.024). The formulation was palatable and well tolerated.
No serious adverse effects were observed between the
groups. The investigators concluded that the PentaHerbs
formulation is efficacious in improving quality of life
and reducing topical corticosteroid use in children with
moderate-to-severe AD.
Shuangfujin Trial
Bai et al. evaluated the effects and safety of Shuangfujin
(SFJ) on acute eczema [31]. One hundred and twenty
patients with acute eczema were randomly assigned to
four groups of same size, namely the saline group, the
boric acid group, the Pifukang lotion group and the SFJ
group. After four days of treatment with the respective
medicine, the symptom score was remarkably lower in
the SFJ group than in the other three groups, score in
the saline group was higher than that in the boric acid
group and the Pifukang lotion group, and difference
between the latter two groups was insignificant. The
effective rate and recovery rate were 46.4% and 14.3% in
the SFJ group, which were equivalent to those in the
Pifukang lotion group and significantly higher than
t h o s ei nt h eo t h e rt w og r o u p s ,a n dt h es a l i n eg r o u p
showed the lowest efficacy. The effects on itchiness in
the SFJ and the boric acid group were matched, which
was higher than those in the Pifukang lotion group, and
the lowest was in the saline group. No skin irritation
and other adverse reactions were found.
Hochu-ekki-to trials
Hochu-ekki-to, a Kampo formula (consisting of 10 herbs,
namely Radix Astragali, Panax ginseng C. A. Mey, Rhi-
zoma Atractylodis Macrocephalae, Glycyrrhiza uralensis,
Angelica sinensis, Citri Reticulatae Pericarpium, Rhi-
zoma Cimicifugae, Radix Bupleuri, Zingiber officinale
Roscoe, Fructus Jujubae Date), is effective for patients
with Kikyo (delicate, easily fatigable, or hypersensitive)
constitution. Previous case reports suggested that this
herbal drug was effective for a subgroup of AD patients.
Kobayashi et al. evaluated the efficacy and safety of
Hochu-ekki-to in the long-term management of Kikyo
patients with AD [32]. In a multicenter, double blind,
randomized, placebo-controlled study, 91 Kikyo patients
with AD were enrolled. Kikyo condition was evaluated
by a questionnaire scoring system. All patients contin-
ued their ordinary treatments (topical steroids, topical
tacrolimus, emollients or oral antihistamines) before and
after their protocol entry. Hochu-ekki-to or placebo was
orally administered twice daily for 24 weeks. The skin
severity scores, total equivalent amount (TEA) of topical
agents used for AD treatment, prominent efficacy (cases
with skin severity score = 0 at the end of the study) rate
and aggravated rate (more than 50% increase of TEA of
topical agents from the beginning of the study) were
monitored and evaluated. Seventy-seven out of 91
enrolled patients completed the 24-week treatment
course (treatment: n = 37, placebo: n = 40). The TEA of
topical agents (steroids and/or tacrolimus was signifi-
cantly lower in the Hochu-ekki-to group than in the pla-
cebo group whereas the overall skin severity scores were
not statistically different. The prominent efficacy rate
was 19% (7 of 37) in the Hochu-ekki-to group and 5% (2
of 40) in the placebo group (P = 0.06). The aggravated
rate was significantly lower in the Hochu-ekki-to group
(3%; 1 of 37) than in the placebo group (18%; 7 of 39).
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were noted in both groups without statistical difference.
This placebo-controlled study demonstrated that Hochu-
ekki-to was a useful adjunct to conventional treatments
for AD patients with Kikyo constitution. Use of Hochu-
ekki-to significantly reduced the dose of topical steroids
and/or tacrolimus used for AD treatment without aggra-
vating AD.
Case series
In the last decades, a number of case series reported the
efficacy of herbal medicine on childhood AD. Luo et al.
reported that fifty-six cases of ‘stubborn’ (’stubborn’ in
Chinese probably meant recalcitrance) eczema treated
by oral administration and topical application of herbal
medicine; [33].
Salameh et al. assessed the effectiveness of the combi-
nation of Chinese herbal medicine and acupuncture for
the treatment of atopic dermatitis [34]. Twenty [20]
mild-to-severe atopic dermatitis patients aged between
13 and 48 years were given a combined treatment of
acupuncture and Chinese herbal medicine and were fol-
lowed prospectively. The patients received acupuncture
treatment twice a week and the Chinese herbal formula
three times daily for a total of 12 weeks. Assessments
were performed before treatment, and at weeks 3, 6, 9
and 12 of treatment. The primary outcomes were
defined as the changes in the Eczema Area and Severity
Index (EASI), Dermatology Life Quality Index (DLQI),
and patient assessment of itch measured on a visual
analogue scale (VAS). After 12 weeks of treatment, an
improvement in EASI over the baseline was noted in
100% of patients. The mean EASI fell from 4.99 to 1.81;
the median percentage of decrease was 63.5%. Moreover,
78.8% of patients experienced a reduction in DLQI and
VAS, as compared with the baseline. The mean DLQI
decreased from 12.5 to 7.6 at the end of treatment, with
39.1% improvement. Mean VAS decreased from 6.8 to
3.7, with 44.7% improvement. No adverse effects were
observed. The authors concluded that the combination
of acupuncture and Chinese herbal medicine had a ben-
eficial effect (reduction of disease severity and improve-
ment of quality of life) on AD patients, probably better
than Chinese herbal medicine alone. As this study
involved heterogeneous age groups of both children and
adults and it was an open-label study, conclusion about
the Chinese herbal medicine cannot be ascertained.
Hon et al. performed a single-center open label trial
to assess the efficacy and tolerability of a Chinese medi-
cine syrup in younger children with AD [35]. Children
aged 4 to 7 years with AD diagnosed according to Hani-
fin and Rajka’s criteria [36] were recruited. The clinical
severity of AD was evaluated according to the SCORing
Atopic Dermatitis (SCORAD) index, [37] and all
subjects had an objective SCORAD score of ≥15 (mod-
erate-to-severe disease) at the entry into this study [38].
At baseline (visit 1), dietary intake, emollient, topical
corticosteroid usage and information regarding the
severity of AD were collected. They then received Chi-
nese herbal medicine syrup 20 ml daily for 12 weeks.
The physicians at the Institute of Chinese Medicine sug-
gested that this dosage (equivalent to a bowel of herbal
tea) would suit a wide range of age groups [28,30].
Enrolled subjects were followed up at two weeks (visit
2), seven weeks (visit 3), 12 weeks (visit 4) and four
weeks after completion of treatment (visit 5) for the
control of their skin condition. Each patient was given
an Eczema Diary for recording daily symptom during
the period prior to each visit. The severity of AD and
quality of life as assessed with the SCORAD index and
Children’s Dermatology Life Quality Index (CDLQI),
r e s p e c t i v e l y[ 3 7 - 3 9 ]a te v e r yv i s i tw e r eu s e da st h ep r i -
mary outcome measures. The individual components
that constitute SCORAD, such as disease extent, inten-
sity, pruritus and sleep loss [37] formed the secondary
outcome measures. The potency of topical CS was not
changed during the study period. The type of oral anti-
histamines used by a particular subject remained the
same throughout the study. Twenty-two Chinese chil-
dren (10 boys and 12 girls), with a mean (Standard
deviation, SD) age of 5.8 (0.9) years, participated in this
study. Their mean (SD) objective SCORAD was 36.6
(12.5), and mean (SD) CDLQI was 11.9 (6.0). There
were significant improvements in the objective
SCORAD, pruritus and CDLQI scores four weeks after
study completion. There was no change in sleep score
or amount of topical steroid consumption. No biochem-
ical evidence of any adverse drug reaction was found
during the study period. The Chinese herbal medicine
syrup was generally palatable and well tolerated by the
children. Adverse effects were mild although two
patients with rash withdrew during the study. The
authors concluded that further evaluations and dosage
studies of the decoction for treating young children
were warranted. The findings in quality of life improve-
ment agreed with the previous randomized placebo-con-
trolled trial with the same decoction in capsular
preparation for older children [30]. The therapeutic
effects persisted one month after treatment had stopped.
Laboratory studies
To delineate the actions of PentaHerbs on AD, the
authors analyzed the effects of an extract of these herbs
on interleukin 4 (IL-4)-induced CD23 expression on
peripheral blood monocytes collected from non-atopic
subjects. They found that PentaHerbs inhibited CD23
expression up to 60% (P < 0.001) whereas the placebo
extract had no significant effect on CD23 expression.
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was effective at a concentration of 250 μg/ml (P =
0.001). If PentaHerbs or placebo was added after IL-4,
the action of PentaHerbs was still observed at 12 hours.
This inhibition was not due to cell death, as peripheral
blood mononuclear cells (PBMCs) cultured with Penta-
Herbs or placebo at a concentration used in these
experiments had a similar viability to control cultures.
Down-regulation of the low affinity receptors for IgE on
antigen-presenting cells in patients with eczema may
contribute to the benefit observed following treatment
with PentaHerbs [40].
Laboratory studies also demonstrated favorable immu-
nomodulatory effects [41,42]. Leung et al. investigated
the immunomodulatory effects possibly induced by Pen-
taHerbs treatment [41] on cytotoxicity and proliferation
of phytohaemagglutinin (PHA)- and staphylococcal
enterotoxin B (SEB)-stimulated peripheral blood mono-
nuclear cells (PBMC) isolated from buffy coat of blood
donors. PentaHerbs-induced immunomodulation for five
inflammatory mediators in cultured PBMC was mea-
sured by reverse transcription-polymerase chain reaction
(RT-PCR) and enzyme-linked immunosorbent assay.
The effects of a 3-month, open-label study of PHF treat-
ment on circulating inflammatory mediators in children
with AD were also assessed. PentaHerbs at up to 1 mg/
mL dose-dependently suppressed PBMC proliferation.
The addition of PentaHerbs to cultured PBMC reduced
supernatant concentrations of brain-derived neuro-
trophic factor (BDNF), interferon (IFN)-gamma and
tumour necrosis factor (TNF)-alpha in response to PHA
and BDNF and thymus and activation-regulated chemo-
kine (TARC) following SEB stimulation. PentaHerbs
increased epithelial cell-derived neutrophil activating
peptide-78 levels in culture supernatants. At the RNA
level, PentaHerbs suppressed the transcription of BDNF,
TARC, IFN-gamma and TNF-alpha. Twenty-eight chil-
dren with AD were treated with PentaHerbs for three
months, and their mean plasma concentrations of BDNF
and TARC decreased significantly from 1798 pg/mL and
824 pg/mL at baseline to 1378 pg/mL and 492 pg/mL
(P = 0.002 and 0.013 respectively) upon study comple-
tion. The invetsigators concluded that PentaHerbs pos-
sessed in vitro and in vivo immunomodulation that
might mediate the clinical efficacy observed in AD treat-
ment with PentaHerbs [41].
The actions of PentaHerbs on mast cell activation was
also investigated [42]. Effects of aqueous extracts of Pen-
taHerbs and individual component herbs on mediator
release from rat peritoneal mast cells (RPMCs) and
cytokine production from HMC-1 were investigated.
PentaHerbs, Cortex Moutan and Herba Menthae signifi-
cantly attenuated histamine release and prostaglandin D
(2) synthesis from RPMC activated by anti-IgE and
compound 48/80. While Flos Lonicerae and Rhizoma
Atractylodis suppressed only mediator release from
compound 48/80 activated RPMC, Cortex Phellodendri
potentiated only anti-IgE induced mediator release.
However, with the exception of Cortex Moutan,P e n t a -
Herbs and the other four component herbs failed to
affect cytokine production in Human Mast Cell HMC-1.
The investigators concluded that individual herbs of
PentaHerbs modulated mast cells and inhibited the
inflammatory mediators from mast cells thereby achiev-
ing the therapeutic efficacy of PentaHerbs.
Adverse effects
Adverse effects of some Chinese herbal medicine have
been reported [11,43-49]. Perharic et al. received reports
of 11 cases of liver damage following the use of Chinese
herbal medicine for skin conditions [48]. There were
two confirmed cases in which recovery after dechallenge
and recurrence of hepatitis after rechallenge were
observed. The time-course relationship, recovery after
ceasing Chinese herbal medicine, and absence of alter-
native causes of liver damage two further symptomatic
cases following a single period of exposure. Herbal
material was available for analysis in seven cases. The
plant mixtures varied and no single ingredient
accounted for the liver injury in this case series. The
mechanism of toxicity was unclear; effects did not
appear dose-related and are probably idiosyncratic. Fer-
guson et al. reported that a patient with eczema devel-
oped a severe cardiomyopathy after a 2-week course of
Chinese herbal medicine [44]. The connection between
cardiomyopathy and usage of Chinese herbal medicine
was not established until when the patient was specifi-
cally asked if she had ingested any unusual substances.
The authors cautioned that patients might not consider
medicinal herbs worth mentioning during a standard
medical history. The indiscriminate usage of herbs by
parents in treating children for prolonged durations is
especially alarming. This concern is increased by the
fact that there is no standardized treatment; it is the
choice of the individual practitioner how much any one
herb is prescribed [43]. Chinese medicine practitioners
have another concern that standardisation of herbal
mixtures may contradict Chinese medicine theories [43].
Conclusion
Only a few RCTs demonstrated the efficacy (or lack of
efficacy) of Chinese medicinal herbs in treating AD.
Further larger scale trials and laboratory studies are
warranted.
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